| Q38186660 | Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: implications for diagnostic microdosing |
| Q35999625 | Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care |
| Q41701820 | Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients |
| Q33263474 | Differential liver protein expression during schistosomiasis |
| Q40190244 | Distribution and variable expression of secretory pathway protein reticulocalbin in normal human organs and non-neoplastic pathological conditions |
| Q49906228 | Downregulation of reticulocalbin-1 differentially facilitates apoptosis and necroptosis in human prostate cancer cells. |
| Q35842082 | Glutathione S-Transferase Gene Polymorphisms and Treatment Outcome in Cervical Cancer Patients under Concomitant Chemoradiation |
| Q34148738 | Identification of candidate biomarkers for early detection of human lung squamous cell cancer by quantitative proteomics |
| Q92874852 | New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment |
| Q26863490 | Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer |
| Q47141445 | Reticulocalbin 2 correlates with recurrence and prognosis in colorectal cancer |
| Q40107969 | Reticulocalbin-2 enhances hepatocellular carcinoma proliferation via modulating the EGFR-ERK pathway. |
| Q33262142 | Shotgun glycopeptide capture approach coupled with mass spectrometry for comprehensive glycoproteomics |
| Q55465293 | The expression and prognostic significance of ERCC1 and GST-pi in lung cancer |